Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 권기환 | * |
dc.date.accessioned | 2016-08-28T11:08:55Z | - |
dc.date.available | 2016-08-28T11:08:55Z | - |
dc.date.issued | 2008 | * |
dc.identifier.issn | 1522-1946 | * |
dc.identifier.other | OAK-13184 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/229215 | - |
dc.description.abstract | Background: There is some controversy on long-term cardiac outcomes between sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) in diabetes mellitus (DM). We compared cardiac adverse events after SES and PES implantation in patients with DM over a period of 3 year. Methods: A total of 634 patients with DM treated with SES (n 5 428) or PES (n 5 206) were consecutively enrolled in the KOMATE registry from 2003 to 2004. We assessed major adverse cardiac events (MACEs, cardiovascular death, non-fatal myocardial infarction, ischemia driven target vessel revascularization) and stent thrombosis (ST) according to the definitions set by the Academic Research Consortium. Results: Propensity score (PS) analysis was performed to adjust different baseline characteristics. The mean follow-up duration was 38 ± 8 month (at least 36 month and up to 53 month). The 3-year MACE rate did not show a significant difference between the two groups [52 (12.1%) in SES vs. 29 (14.1%) in PES, P = 0.496]. The definite and probable ST at 3 year were similar in both SES and PES [12 (2.8%) in SES vs. 7 (3.4%) in PES, P = 0.681]. There were no differences in hazard ratio for MACE and ST between two stents [MACE, crude: 0.844 (0.536-1.330) and adjusted for PS: 0.858 (0.530-1.389); ST, crude: 0.820 (0.323-2.083) and adjusted for PS: 0.960 (0.357-2.587)]. Conclusions: The present study demonstrated that long-tem cardiac outcomes including ST were not significantly different between SES and PES in patients with DM. © 2008 Wiley-Liss, Inc. | * |
dc.language | English | * |
dc.title | Comparison of sirolimus-eluting stent and paclitaxel-eluting stent for long-term cardiac adverse events in diabetic patients: The Korean multicenter angioplasty team (KOMATE) registry | * |
dc.type | Article | * |
dc.relation.issue | 5 | * |
dc.relation.volume | 72 | * |
dc.relation.index | SCI | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 601 | * |
dc.relation.lastpage | 607 | * |
dc.relation.journaltitle | Catheterization and Cardiovascular Interventions | * |
dc.identifier.doi | 10.1002/ccd.21700 | * |
dc.identifier.scopusid | 2-s2.0-58749099139 | * |
dc.author.google | Kim J.-S. | * |
dc.author.google | Lee B.H. | * |
dc.author.google | Ko Y.-G. | * |
dc.author.google | Choi D. | * |
dc.author.google | Jang Y. | * |
dc.author.google | Min P.-K. | * |
dc.author.google | Yoon Y.-W. | * |
dc.author.google | Hong B.K. | * |
dc.author.google | Kwon H.M. | * |
dc.author.google | Ahn M.-S. | * |
dc.author.google | Lee S.-H. | * |
dc.author.google | Yoon J.H. | * |
dc.author.google | Lee B.K. | * |
dc.author.google | Kim B.O. | * |
dc.author.google | Kim B.-K. | * |
dc.author.google | Oh S.J. | * |
dc.author.google | Jeon D.W. | * |
dc.author.google | Yang J.Y. | * |
dc.author.google | Cho J.R. | * |
dc.author.google | Jung J.-H. | * |
dc.author.google | Ryu S.-K. | * |
dc.author.google | Kwon K. | * |
dc.author.google | Park S.H. | * |
dc.author.google | Byun Y.S. | * |
dc.author.google | Ko C.W. | * |
dc.contributor.scopusid | 권기환(57203037966) | * |
dc.date.modifydate | 20240118164632 | * |